Jupiter Neurosciences, INC Form 4 insider transactions

Andrew Jon Cutler, a Director of Jupiter Neurosciences, Inc., received 472,222 shares of common stock on July 31, 2026.

Julie B. Kampf, a Director of Jupiter Neurosciences, Inc., reported multiple transactions in common stock on June 2, 2025.

Alexander Gustaf Erik Rosen, Chief Administrative Officer of Jupiter Neurosciences, Inc., reported multiple transactions in common stock on June 2, 2025.

Marshall A. Hayward, Chief Scientific Officer and a Director of Jupiter Neurosciences, Inc., reported multiple transactions in common stock on June 2, 2025.

Nicholas H. Hemmerly, a Director of Jupiter Neurosciences, Inc., reported multiple transactions in common stock on June 2, 2025.

Holger Weis, a Director of Jupiter Neurosciences, Inc., reported multiple transactions in common stock on June 2, 2025.

Jupiter Neurosciences, Inc. reports a grant of stock options to Director Tomas Jan Philipson, with a portion tied to his board appointment and the remainder in lieu of cash compensation.

Director Allison W. Brady was granted 100,000 stock options in Jupiter Neurosciences, Inc. under the 2025 Equity Incentive Plan.

Jupiter Neurosciences CFO Saleem Elmasri was granted 525,565 stock options as part of a discretionary and long-term incentive plan.

CEO and Chairman Christer Rosen was granted 747,783 stock options as a discretionary bonus for 2025 fiscal performance.

Director Nicholas H. Hemmerly was granted 100,000 stock options in Jupiter Neurosciences, Inc. under the 2025 Equity Incentive Plan.

Director Julie B. Kampf was granted 100,000 stock options in Jupiter Neurosciences, Inc. under the 2025 Equity Incentive Plan.

President and COO Alison D. Silva was granted 1,027,304 stock options as part of the company's 2025 Equity Incentive Plan.

Chief Scientific Officer Marshall A. Hayward was granted 259,231 stock options as a discretionary bonus for 2025 services.

Director Holger Weis was granted 100,000 stock options in Jupiter Neurosciences, Inc. under the 2025 Equity Incentive Plan.

Chief Administrative Officer Alexander Rosen received a grant of 341,843 stock options as a discretionary bonus.

Jupiter Neurosciences, Inc.'s CFO and Secretary, Saleem Elmasri, has reported the vesting of restricted stock units and the grant of new stock options as part of his compensation.

Jupiter Neurosciences, Inc. has granted 255,320 stock options to Alison D. Silva, President and Chief Business Officer, as a discretionary bonus for fiscal 2024 services, vesting over three years starting July 2, 2025.

Alison D. Silva, President and Chief Business Officer of Jupiter Neurosciences, Inc., has acquired 750 shares of common stock through open market purchases, increasing her direct beneficial ownership to 112,777 shares.

Christer Rosen, CEO and Chairman of Jupiter Neurosciences, Inc., has increased his direct beneficial ownership in the company through recent common stock purchases.

Alison D. Silva, President and Chief Business Officer of Jupiter Neurosciences, Inc., increased her direct beneficial ownership of common stock to 112,027 shares through the vesting of restricted stock units and subsequent open market purchases in June 2025.

Christer Rosen, CEO and Chairman of Jupiter Neurosciences, Inc., reported substantial acquisitions of common stock through both vesting of equity awards and open market purchases in June 2025.

Director Holger Weis converted convertible notes into 10,781 shares of common stock in Jupiter Neurosciences.

Director Allison W. Brady converted convertible notes into 21,750 shares of common stock in Jupiter Neurosciences.